权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Antiviral & Antimicrobial Countermeasures Discovery and Development Core

抗病毒物质

基本信息

批准号：
10793955
负责人：
Colleen B Jonsson
金额：
$ 121.61万
依托单位：
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-08-18 至 2028-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10793955
关键词：
Abbreviations Animal Model Award Biomedical Research Communication Consumption Containment Development Drug Exposure Educational workshop Equipment Funding Goals Histology Human Image Immunohistochemistry In Vitro Infection Laboratories Maintenance Manuals Mass Spectrum Analysis Mission Paraffin Embedding Paraffin Tissue Pharmaceutical Preparations Pharmacodynamics Phase Procedures Process RNA Viruses Research Services Site Specialist Targeted Research Therapeutic Time Tissues Training Vendor Viral Work X-Ray Computed Tomography animal tissue antimicrobial drug development drug discovery efficacy study experience good laboratory practice imaging modality improved in vivo infectious disease model instrument instrumentation laboratory facility liquid chromatography mass spectrometry operation pathogen pre-clinical assessment preclinical development promote resilience prophylactic screening small molecule

项目摘要

PROJECT ABSTRACT The proposed Antiviral & Antimicrobial Countermeasures Discovery & Development Core (herein abbreviated as A2CD2C) will facilitate biomedical research targeted toward the discovery and/or development of countermeasures for prophylactic or therapeutic treatment of human biosafety level 3 (BSL-3) pathogens or BSL-2 pathogens that mandate select agent control. The A2CD2C will enable this research using state-of-the-art equipment for small molecule (1) screening, (2) imaging, (3) liquid chromatography-mass spectrometry (LCMS/MS) services and (4) histology. The core will be housed within the UTHSC Regional Biocontainment Laboratory (RBL) in BSL-3 space. The A2CD2C is significant in that it provides an efficient, integrated, comprehensive platform that will facilitate studies from the initial discovery phase through pre-clinical development within BSL-3 containment. The A2CD2C is unique within the RBL network in its focus on providing LC-MS studies for infected, treated animal tissues in BSL-3 to provide much needed information of the site of exposure of the therapeutic at the site of infection and thereby providing important pharmacodynamic information required for preclinical assessment. The major mission of the A2CD2C is to maintain, improve and expand our RBL support services in drug discovery and development with a focus on drug pharmacodynamics in terms of how and how much drug exposure impacts pathogen survival. We propose three objectives to achieve herein: Objective 1. To maintain A2CD2C support services in drug discovery and development; Objective 2. To improve A2CD2C support services in drug discovery and development; and Objective 3. To expand A2CD2C support services in imaging in drug discovery and development.

项目摘要所提出的抗病毒和抗微生物对策发现和开发核心（本文缩写为A2 CD 2C）将促进以发现和/或开发为目标的生物医学研究预防或治疗人类生物安全3级（BSL-3）病原体的对策，或 BSL-2病原体要求进行选择性病原体控制。A2 CD 2C将利用最先进的技术小分子设备（1）筛选，（2）成像，（3）液相色谱-质谱 (LCMS/MS）服务和（4）组织学。该核心将被安置在UTHSC区域生物安全壳内 BSL-3空间的RBL实验室。A2 CD 2C的重要性在于它提供了一种有效的、集成的、全面的平台，将促进从最初发现阶段到临床前的研究在BSL-3安全壳内进行开发。A2 CD 2C在RBL网络中是独一无二的，其重点是提供在BSL-3中对感染的、处理的动物组织进行LC-MS研究，以提供急需的感染部位信息。治疗剂暴露在感染部位，从而提供重要的药效学信息进行临床前评估。 A2 CD 2C的主要使命是维持、改善和扩大我们在药物方面的RBL支持服务。发现和开发，重点是药物药效学，即如何和多少药物暴露影响病原体存活。我们提出了三个目标，以实现在这里：目标1。保持 A2 CD 2C药物发现和开发的支持服务;目标2。改善A2 CD 2C支持服务药物发现和开发;以及目标3。扩大A2 CD 2C在药物成像方面的支持服务发现和发展。